These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38614068)

  • 41. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
    Zamora C; Riudavets M; Anguera G; Alserawan L; Sullivan I; Barba A; Serra J; Ortiz MA; Gallardo P; Perea L; Gavira J; Barnadas A; Majem M; Vidal S
    Cancer Immunol Immunother; 2021 Jun; 70(6):1691-1704. PubMed ID: 33388994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Yi L; Zeng X; Zhou Z; Liu Q
    Adv Ther; 2024 Aug; 41(8):3159-3172. PubMed ID: 38888881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
    Ou SL; Luo J; Wei H; Qin XL; Du SY; Wang S; Jiang Q
    Front Immunol; 2022; 13():953761. PubMed ID: 35911744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.
    Li B; Jiang C; Pang L; Zou B; Ding M; Sun X; Yu J; Wang L
    Front Immunol; 2021; 12():627197. PubMed ID: 33859637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
    Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
    N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment.
    Zarogoulidis P; Matthaios D; Oikonomou P; Nikolaou C; Charalampidis C; Sardeli C
    Cancer Treat Res Commun; 2023; 37():100757. PubMed ID: 37666686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
    J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CodeBreak 200: Sotorasib Has Not Broken the KRAS
    Zhang SS; Lee A; Nagasaka M
    Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 55. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
    Mark M; Froesch P; Eboulet EI; Addeo A; Pless M; Rothschild SI; Janthur WD; Burmeister H; Friedlaender A; Schneider M; Metaxas Y; Joerger M; Wannesson L; Schwitter M; Baudoux N; Weindler S; Biaggi-Rudolf C; Früh M;
    Cancer Immunol Immunother; 2021 May; 70(5):1255-1262. PubMed ID: 33130956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
    BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
    Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
    Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.